GlassScriptPhysician profile
Roy Jeffrey Moen
NPI 1528092772
$1,285.94
in general payments reported to CMS, 2019-2025
28 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $23.15 · 2022: $37.40 · 2023: $18.65 · 2024: $273 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.83 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $109.14 | 2025 | |
| Abbvie INC. | $92.21 | 2021-2025 | |
| Pfizer INC. | $88.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $81.89 | 2024-2025 | Camzyos |
| Lilly USA, LLC | $80.36 | 2024-2025 | Mounjaro, Zepbound, Omvoh |
| Janssen Pharmaceuticals, INC | $78.13 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $69.24 | 2024-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $68.01 | 2025 | Gattex, Trintellix, Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.07 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $48.31 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $44.19 | 2025 | Voquezna |
| Amgen INC. | $43.50 | 2024-2025 | Evenity, Otezla, Repatha |
| Axsome Therapeutics, INC. | $36.00 | 2025 | Auvelity |
| Madrigal Pharmaceuticals | $29.20 | 2025 | Rezdiffra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.73 | 2025 | Caplyta |
| Calliditas Therapeutics US INC. | $23.70 | 2024 | |
| Aimmune Therapeutics, INC. | $23.29 | 2025 | Zenpep |
| Ardelyx, INC. | $19.31 | 2025 | Ibsrela |
| Mylan Specialty L.P. | $18.84 | 2019 | |
| Qol Medical, LLC | $18.07 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $17.75 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.56 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $14.69 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $13.86 | 2024 | Jynarque |
| Exact Sciences Corporation | $13.78 | 2025 | The Cologuard Plus Collection Kit |
| Aurinia Pharma U.S., INC. | $13.70 | 2024 | Lupkynis |
| Merck Sharp & Dohme LLC | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Moen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.